The response of vasculitis patients to influenza vaccination compared to healthy individuals
Phase 4
Completed
- Conditions
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitisInflammatory and Immune System - Autoimmune diseases
- Registration Number
- ACTRN12608000440325
- Lead Sponsor
- Royal Adelaide Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients: Have biopsy-proven ANCA (Anti-neutrophil cytoplasmic antibodies) vasculitis and are currently in remission.
Healthy controls: Fit and well with no significant infection in the past month.
Exclusion Criteria
Patients: Received an organ transplant, have end-stage renal failure, have a contraindication to receiving the influenza vaccine including egg allergy, pregnant
Controls: Diabetes, receiving any oral immunosuppressant therapy, Pregnancy, any significant end-organ disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome: Immunological response to the influenza vaccine measured by haemagglutination-inhibition assays (HAI)[Day 0, Day 7 and Day 28]
- Secondary Outcome Measures
Name Time Method